Such findings were presented at the recently held Society for Neuro-Oncology's 11th Annual Meeting in Orlando, FL.
According to William R. Shapiro, M.D., chief of the Neuro-Oncology Division of Neurology at the Barrow Neurological Institute, and presenter of the pooled Phase 3 results:
"These data demonstrate that Xcytrin, used in combination with whole brain radiation therapy, may significantly improve neurologic outcomes in patients with brain metastases from non-small cell lung cancer.”These two large studies both used an innovative and clinically meaningful endpoint and reveal consistent benefit in this patient population."
Xcytrin® is Pharmacyclics’ lead anti-cancer agent with a novelly-designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Xcytrin®, a redox-active drug, has been shown to disrupt redox-dependent pathways in cells and inhibit oxidative stress related proteins: the multifunctional mode of action provides the opportunity to be used in a broad range of cancers.
Find more details from the press release.
[Photo Credit: Gamma Knife Center]
Comment Preview